IBT
AMGN icon

International Biotechnology Trust’s Amgen AMGN Stock Holding History

International Biotechnology Trust’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$21.3M Sell
79,246
-38,000
-32% -$9.48M 7.17% 1
2023
Q2 		$26M Buy
117,246
+26,000
+28% +$6.03M 7.92% 1
2023
Q1 		$22.1M Buy
91,246
+75,000
+462% +$18.4M 6.15% 2
2022
Q4 		$4.27M Hold
16,246
– – 1.32% 25
2022
Q3 		$3.66M Buy
16,246
+6,331
+64% +$1.53M 1.17% 27
2022
Q2 		$40.7K Sell
9,915
-56,831
-85% -$13.9M 0.43% 48
2022
Q1 		$32.6M Sell
66,746
-78,000
-54% -$17.9M 7.34% 1
2021
Q4 		$32.6M Buy
144,746
+26,446
+22% +$5.58M 7.26% 1
2021
Q3 		$25.1M Buy
118,300
+67,300
+132% +$15.5M 6.06% 4
2021
Q2 		$12.4M Buy
51,000
+8,000
+19% +$1.97M 3.28% 11
2021
Q1 		$10.7M Sell
43,000
-29,000
-40% -$6.92M 2.83% 15
2020
Q4 		$16.5M Buy
72,000
+28,000
+64% +$6.46M 4.52% 8
2020
Q3 		$11.2M Sell
44,000
-8,000
-15% -$1.98M 3.61% 11
2020
Q2 		$12M Sell
52,000
-14,000
-21% -$3.19M 4% 10
2020
Q1 		$13.4M Hold
66,000
– – 6.1% 6
2019
Q4 		$15.9M Hold
66,000
– – 5.73% 3
2019
Q3 		$12.8M Hold
66,000
– – 5.9% 5
2019
Q2 		$12.2M Buy
66,000
+42,000
+175% +$7.52M 4.51% 6
2019
Q1 		$4.56M Hold
24,000
– – 1.68% 23
2018
Q4 		$3.67M Buy
+24,000
New +$4.68M 2.28% 16
2018
Q1 		– Sell
-36,104
Closed -$6.28M – 64
2017
Q4 		$6.28M Hold
36,104
– – 2.21% 16
2017
Q3 		$6.73M Sell
36,104
-14,000
-28% -$2.48M 2.62% 10
2017
Q2 		$8.63M Sell
50,104
-17,000
-25% -$2.77M 3.28% 8
2017
Q1 		$11M Sell
67,104
-13,000
-16% -$2.16M 4.21% 8
2016
Q4 		$11.7M Buy
+80,104
New +$12.1M 5.28% 8

Other funds holding AMGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

International Biotechnology Trust's AMGN Position: Q3 2023 in Review

International Biotechnology Trust reduced its Amgen (AMGN) stake by 32% in Q3 2023, selling an estimated $9.48M and leaving 79,246 shares worth $21.3M. The position accounts for 7.17% of the portfolio, ranked #1.

International Biotechnology Trust first reported a position in AMGN in Q4 2016 and has held it in 25 quarters since. The position peaked at $32.6M in Q1 2022. 2,502 funds tracked by Wall St. Rank hold AMGN as of Q3 2023.

  • International Biotechnology Trust held 79,246 shares of Amgen worth $21.3M as of Q3 2023.
  • International Biotechnology Trust sold 38,000 Amgen shares in Q3 2023, an estimated $9.48M.
  • Amgen made up 7.17% of International Biotechnology Trust's portfolio in Q3 2023, its #1 holding.
  • International Biotechnology Trust first reported a position in Amgen in Q4 2016 and has held it in 25 quarters since.
  • International Biotechnology Trust's Amgen position peaked at $32.6M in Q1 2022.
  • 2,502 funds tracked by Wall St. Rank held Amgen as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.